Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Heron Therapeutics (HRTX) over the last 10 years, with Dec 2024 value amounting to $123.5 million.

  • Heron Therapeutics' Change in Acquisitions & Divestments fell 40.24% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.3 million, marking a year-over-year decrease of 25.97%. This contributed to the annual value of $123.5 million for FY2024, which is 15.20% up from last year.
  • Per Heron Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $123.5 million for FY2024, which was up 15.20% from $107.2 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Change in Acquisitions & Divestments ranged from a high of $349.8 million in FY2020 and a low of $107.2 million during FY2023.
  • For the 3-year period, Heron Therapeutics' Change in Acquisitions & Divestments averaged around $124.9 million, with its median value being $123.5 million (2024).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first plummeted by 52.84% in 2021, then rose by 15.20% in 2024.
  • Yearly analysis of 5 years shows Heron Therapeutics' Change in Acquisitions & Divestments stood at $349.8 million in 2020, then slumped by 52.84% to $164.9 million in 2021, then dropped by 12.72% to $144.0 million in 2022, then dropped by 25.54% to $107.2 million in 2023, then increased by 15.20% to $123.5 million in 2024.